These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 30259401)

  • 41. Suitability of differently formulated dry powder Newcastle disease vaccines for mass vaccination of poultry.
    Huyge K; Van Reeth K; De Beer T; Landman WJ; van Eck JH; Remon JP; Vervaet C
    Eur J Pharm Biopharm; 2012 Apr; 80(3):649-56. PubMed ID: 22155763
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Topical imiquimod before intradermal trivalent influenza vaccine for protection against heterologous non-vaccine and antigenically drifted viruses: a single-centre, double-blind, randomised, controlled phase 2b/3 trial.
    Hung IF; Zhang AJ; To KK; Chan JF; Li P; Wong TL; Zhang R; Chan TC; Chan BC; Wai HH; Chan LW; Fong HP; Hui RK; Kong KL; Leung AC; Ngan AH; Tsang LW; Yeung AP; Yiu GC; Yung W; Lau JY; Chen H; Chan KH; Yuen KY
    Lancet Infect Dis; 2016 Feb; 16(2):209-18. PubMed ID: 26559482
    [TBL] [Abstract][Full Text] [Related]  

  • 43. N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model.
    Amidi M; Romeijn SG; Verhoef JC; Junginger HE; Bungener L; Huckriede A; Crommelin DJ; Jiskoot W
    Vaccine; 2007 Jan; 25(1):144-53. PubMed ID: 16973248
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of a novel microcrystalline tyrosine adjuvant with aluminium hydroxide for enhancing vaccination against seasonal influenza.
    Heath MD; Swan NJ; Marriott AC; Silman NJ; Hallis B; Prevosto C; Gooch KE; Skinner MA
    BMC Infect Dis; 2017 Mar; 17(1):232. PubMed ID: 28347293
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Composition of the Stabilizer and Conditions of Lyophilization for Preserving Infectious Activity of Influenza Virus.
    Dubrovina IA; Kiseleva IV; Kireeva EV; Rudenko LG
    Bull Exp Biol Med; 2018 May; 165(1):52-56. PubMed ID: 29796807
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rational design of an influenza subunit vaccine powder with sugar glass technology: preventing conformational changes of haemagglutinin during freezing and freeze-drying.
    Amorij JP; Meulenaar J; Hinrichs WL; Stegmann T; Huckriede A; Coenen F; Frijlink HW
    Vaccine; 2007 Aug; 25(35):6447-57. PubMed ID: 17673338
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunogenicity and efficacy of the monovalent, trivalent and quadrivalent intranasal live attenuated influenza vaccines containing different pdmH1N1 strains.
    Yeolekar LR; Ganguly M; Tyagi P; Ingle NB; Stittelaar KJ; Waal L; Scorza FB; Mahmood K; Dhere RM
    Vaccine; 2018 Nov; 36(46):6944-6952. PubMed ID: 30322745
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant.
    Sui Z; Chen Q; Fang F; Zheng M; Chen Z
    Vaccine; 2010 Nov; 28(48):7690-8. PubMed ID: 20870054
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The quest for a nanoparticle-based vaccine inducing broad protection to influenza viruses.
    Bolduc M; Baz M; Laliberté-Gagné MÈ; Carignan D; Garneau C; Russel A; Boivin G; Savard P; Leclerc D
    Nanomedicine; 2018 Nov; 14(8):2563-2574. PubMed ID: 30193813
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma.
    Fleming DM; Crovari P; Wahn U; Klemola T; Schlesinger Y; Langussis A; Øymar K; Garcia ML; Krygier A; Costa H; Heininger U; Pregaldien JL; Cheng SM; Skinner J; Razmpour A; Saville M; Gruber WC; Forrest B;
    Pediatr Infect Dis J; 2006 Oct; 25(10):860-9. PubMed ID: 17006278
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antigenic variation of H1N1, H1N2 and H3N2 swine influenza viruses in Japan and Vietnam.
    Takemae N; Nguyen T; Ngo LT; Hiromoto Y; Uchida Y; Pham VP; Kageyama T; Kasuo S; Shimada S; Yamashita Y; Goto K; Kubo H; Le VT; Van Vo H; Do HT; Nguyen DH; Hayashi T; Matsuu A; Saito T
    Arch Virol; 2013 Apr; 158(4):859-76. PubMed ID: 23435952
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inhalable dry powder formulations of siRNA and pH-responsive peptides with antiviral activity against H1N1 influenza virus.
    Liang W; Chow MY; Lau PN; Zhou QT; Kwok PC; Leung GP; Mason AJ; Chan HK; Poon LL; Lam JK
    Mol Pharm; 2015 Mar; 12(3):910-21. PubMed ID: 25599953
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
    Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Preparation of zolmitriptan-chitosan microparticles by spray drying for nasal delivery.
    Alhalaweh A; Andersson S; Velaga SP
    Eur J Pharm Sci; 2009 Oct; 38(3):206-14. PubMed ID: 19616094
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase I/II trial of a replication-deficient trivalent influenza virus vaccine lacking NS1.
    Mössler C; Groiss F; Wolzt M; Wolschek M; Seipelt J; Muster T
    Vaccine; 2013 Dec; 31(52):6194-200. PubMed ID: 24183981
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Drying-induced variations in physico-chemical properties of amorphous pharmaceuticals and their impact on Stability II: stability of a vaccine.
    Abdul-Fattah AM; Truong-Le V; Yee L; Pan E; Ao Y; Kalonia DS; Pikal MJ
    Pharm Res; 2007 Apr; 24(4):715-27. PubMed ID: 17372697
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Germacrone inhibits early stages of influenza virus infection.
    Liao Q; Qian Z; Liu R; An L; Chen X
    Antiviral Res; 2013 Dec; 100(3):578-88. PubMed ID: 24095670
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Y161F Hemagglutinin Substitution Increases Thermostability and Improves Yields of 2009 H1N1 Influenza A Virus in Cells.
    Wen F; Li L; Zhao N; Chiang MJ; Xie H; Cooley J; Webby R; Wang PG; Wan XF
    J Virol; 2018 Jan; 92(2):. PubMed ID: 29118117
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Preparation, characterization and immunological evaluation of alginate nanoparticles loaded with whole inactivated influenza virus: Dry powder formulation for nasal immunization in rabbits.
    Dehghan S; Kheiri MT; Abnous K; Eskandari M; Tafaghodi M
    Microb Pathog; 2018 Feb; 115():74-85. PubMed ID: 29223454
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dry-powder form of chitosan nanospheres containing influenza virus and adjuvants for nasal immunization.
    Dehghan S; Tavassoti Kheiri M; Tabatabaiean M; Darzi S; Tafaghodi M
    Arch Pharm Res; 2013 Aug; 36(8):981-92. PubMed ID: 23568383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.